Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of an Exclusive Patent License: Compositions, Devices and Processes for Production and Delivery of Cell Grafts of Manufactured Retinal Pigment Epithelium Cell(s) Alone, or in Combination With Photoreceptor Cells, and on a Biodegradable Support Scaffold Transplanted Subretinally for Intra-Ocular Ophthalmic Treatment of Conditions of Degeneration, Dysfunction or Terminal Injury of Retinal Pigment Epithelium and/or Photoreceptors in Humans Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before October 18, 2019 will be considered.
View Prospective Grant of Exclusive Patent License: Capsid-Free AAV Vectors, Compositions, and Methods for Vector Production and Gene Delivery Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development within 15 days from the date of publication of this notice in the Federal Register will be considered.
View Prospective Grant of an Exclusive Patent License: Genetically-Modified Lymphocytes for Cancer Therapy Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before September 13, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD19/CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before September 19, 2019 will be considered.
View National Institutes of Health Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 23, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Autologus Therapy Using Bicistronic Chimeric Antigen Receptors Targeting CD19 and CD20 Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 29, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Bicistronic Chimeric Antigen Receptors Targeting CD19 and CD20 Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 29, 2019 will be considered.
View Prospective Grant of Exclusive Patent License: Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development July 2, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 2, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: The Development and Use of a Therapeutic STAT3 Inhibitor, GLG-302, in All Proliferative Diseases, Where STAT3 Is Present Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before June 7, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: RP2 AAV Vectors for Treating X-Linked Retinitis Pigmentosa Only written comments and/or applications for a license which are received by the National Eye Institute c/o National Cancer Institute's Technology Transfer Center on or before June 3, 2019 will be considered.
View Prospective Grant of Exclusive Patent License: Scopolamine Therapeutics for Depression and Bipolar Disorder Only written comments and/or applications for a license which are received by the NIMH Technology Transfer Office May 20, 2019 will be considered.
View Prospective Grant of an Exclusive/Co-Exclusive Patent License: Development and Commercialization of Next Generation Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like tyrosine kinase 3 (FLT3) Expressing Cancers Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 19, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: “Treatment of Acute Lymphoblastic Leukemia, T-Cell Lymphoma, and Non-Small Cell Lung Cancer Using the 4A10 Antibody and Fragments Thereof” Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 4, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 22, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Virus-Like Particles Vaccines Against Human Polyomaviruses, BK Virus (BKV) and JC Virus (JCV) Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 22, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Use of the CD47 Phosphorodiamidate Morpholino Oligomers for the Treatment, Prevention, and Diagnosis of Solid Tumors Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before February 20, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: “Multifunctional RNA Nanoparticles and Methods of Uses” and “RNA/DNA Hybrid Nanoparticles Modified With Single Stranded RNA Toeholds and Uses Thereof” Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 7, 2019 will be considered.
View Prospective Grant of Co-Exclusive Patent License: Production of Monovalent Live Attenuated Zika Vaccines and Multivalent Live Attenuated Zika and Dengue Vaccines Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before January 22, 2019 will be considered.
View Prospective Grant of Exclusive Patent License: Production of Monovalent Live Attenuated Zika Vaccines and Multivalent Live Attenuated Zika and Dengue Vaccines Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before January 22, 2019 will be considered.
View Prospective Grant of Exclusive Patent License: Production of Live Respiratory Syncytial Virus and Parainfluenza Virus Vaccines Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before January 7, 2019 will be considered.
View Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 17, 2018 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Cancers Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 4, 2018 will be considered.
View Prospective Grant of Exclusive Patent License: Therapeutics for Insulin Resistance and Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NASH/NAFLD) Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development November 21, 2018 will be considered.
View Prospective Grant of an Exclusive Patent License: Development and Commercialization of Cell Therapies for Cancer Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before October 15, 2018 will be considered.